Evidence map›Paper›PMID 30194412›Full record

ArticleNature medicine2018

Right data for right patient-a precisionFDA NCI-CPTAC Multi-omics Mislabeling Challenge.

Emily Boja, Živana Težak, Bing Zhang, Pei Wang, Elaine Johanson, Denise Hinton, Henry Rodriguez

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Decoding Ubiquitin Modifications by Mass Spectrometry.Advances in experimental medicine and biology · 2024
    Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Clinical metagenomics.Nature reviews. Genetics · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Emily BojaOffice of Cancer Clinical Proteomics Research, Center for Strategic Scientific Initiatives, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. emily.boja@nih.gov.
Živana TežakOffice of In Vitro Diagnostics and Radiological Health, Center for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, MD, USA. zivana.tezak@fda.hhs.gov.
Bing ZhangDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.
Pei WangDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Elaine JohansonOffice of Health Informatics, Office of the Chief Scientist, Office of the Commissioner, US Food and Drug Administration, Silver Spring, MD, USA.
Denise HintonOffice of the Chief Scientist, Office of the Commissioner, US Food and Drug Administration, Silver Spring, MD, USA.
Henry RodriguezOffice of Cancer Clinical Proteomics Research, Center for Strategic Scientific Initiatives, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Funding

Systems Biology based Proteogenomic Translator for Cancer Marker Discovery towards Precision MedicineU24CA210993 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI SCHADT, ERIC E, WANG, PEI · 2016 to 2020
$4.6M
NCI NIH HHS U24 CA210993
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

GenomicsNational Cancer Institute (U.S.)ProteomicsStaining and LabelingUnited States Food and Drug AdministrationHumansUnited States

Identifiers

PMID30194412
PMCPMC6892367

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.